Ratings Standard BioTools Inc.

Equities

LAB

US34385P1084

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
2.71 ^USD	-2.17%		-7.19%	+22.62%

02:16pm	TD Cowen Starts Standard BioTools With Buy Rating, $3.50 Price Target	MT
Apr. 08	Standard BioTools Inc. Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the Boundaries of Tissue Imaging	CI

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
STANDARD BIOTOOLS INC.	+22.62%	1.06B	C-
THERMO FISHER SCIENTIFIC	+4.48%	213B	B
DANAHER CORPORATION	+3.89%	177B	B-
INTUITIVE SURGICAL, INC.	+12.21%	134B	B-
BOSTON SCIENTIFIC CORPORATION	+17.83%	99.13B	A-
SIEMENS HEALTHINEERS AG	+0.11%	63.47B	A-
EDWARDS LIFESCIENCES CORPORATION	+18.10%	53.69B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-4.51%	46.36B	B+
AGILENT TECHNOLOGIES, INC.	-1.60%	41.09B	A
GE HEALTHCARE TECHNOLOGIES INC.	+11.07%	39.3B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes